Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis

Genes and Development

Volumn 24, Issue 15, 2010, Pages 1659-1672

  Klusmann, Jan Henning ^a,b   Godinho, Frank J ^a,c   Heitmann, Kirsten ^b   Maroz, Aliaksandra ^b   Koch, Mia Lee ^b,d   Reinhardt, Dirk ^b   Orkin, Stuart H ^a,c,e,f,g   Li, Zhe ^a,d,e,f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD STEM CELL INSTITUTE   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Down syndrome; DS AMKL; GATA1; IGF signaling; IGF1R; Megakaryoblastic leukemia

Indexed keywords

SOMATOMEDIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GATA 1; GATA1 PROTEIN, HUMAN; GATA1 PROTEIN, MOUSE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR DP1;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DOWN SYNDROME; FETUS; FETUS DEVELOPMENT; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STEM CELL; TRISOMY 21; ANIMAL; CELL STRAIN K 562; CELL SURVIVAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MEGAKARYOBLAST; METABOLISM; MUTATION; ONCOGENE MYC; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN BINDING; THROMBOCYTOPOIESIS; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DOWN SYNDROME; E2F TRANSCRIPTION FACTORS; FETUS; GATA1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, LEUKEMIC; GENE KNOCKDOWN TECHNIQUES; GENES, MYC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; K562 CELLS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MEGAKARYOCYTE PROGENITOR CELLS; MICE; MUTATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SOMATOMEDINS; THROMBOPOIESIS; TRANSCRIPTION FACTOR DP1;

EID: 77955870488     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1903410     Document Type: Article

References (51)

1. Alford KA, Slender A, Vanes L, Li Z, Fisher EM, Nizetic D, Orkin SH, Roberts I, Tybulewicz VL. 2010. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 115: 2928-2937.
2. Baker J, Liu JP, Robertson EJ, Efstratiadis A. 1993. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75: 73-82. (Pubitemid 23306022)
3. Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, et al. 2006. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci 103: 3339-3344. (Pubitemid 43346471)
4. Bowie MB, McKnight KD, Kent DG, McCaffrey L, Hoodless PA, Eaves CJ. 2006. Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. J Clin Invest 116: 2808-2816. (Pubitemid 44511644)
5. Chou S, Lodish HF. 2010. Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. Proc Natl Acad Sci 107: 7799-7804.
6. Chou ST, Opalinska JB, Yao Y, Fernandes MA, Kalota A, Brooks JS, Choi JK, Gewirtz AM, Danet-Desnoyers GA, Nemiroff RL, et al. 2008. Trisomy 21 enhances human fetal erythromegakaryocytic development. Blood 112: 4503-4506.
7. DeChiara TM, Efstratiadis A, Robertson EJ. 1990. A growth deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345: 78-80. (Pubitemid 20152456)
8. DeChiara TM, Robertson EJ, Efstratiadis A. 1991. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64: 849-859. (Pubitemid 121001171)
9. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. 2005. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 37: 1289-1295. (Pubitemid 41568715)
10. Du Y, Jenkins NA, Copeland NG. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood 106: 3932-3939. (Pubitemid 41739034)
11. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. 2003. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101: 4333-4341. (Pubitemid 36857797)
12. Ge Y, Dombkowski AA, LaFiura KM, Tatman D, Yedidi RS, Stout ML, Buck SA, Massey G, Becton DL, Weinstein HJ, et al. 2006. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood 107: 1570-1581. (Pubitemid 43242396)
13. Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW. 2008. The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22: 521-529. (Pubitemid 351386721)
14. Guy CT, Zhou W, Kaufman S, Robinson MO. 1996. E2F-1 blocks terminal differentiation and causes proliferation in transgenic megakaryocytes. Mol Cell Biol 16: 685-693. (Pubitemid 26029628)
15. Hasle H. 2001. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2: 429-436. (Pubitemid 33585947)
16. Hock H, Meade E, Medeiros S, Schindler JW, Valk PJ, Fujiwara Y, Orkin SH. 2004. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. Genes Dev 18: 2336-2341. (Pubitemid 39304679)
17. Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF. 2006. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38: 807-812. (Pubitemid 43980602)
18. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. 2002. A stem cell molecular signature. Science 298: 601-604.
19. Kadri Z, Shimizu R, Ohneda O, Maouche-Chretien L, Gisselbrecht S, Yamamoto M, Romeo PH, Leboulch P, Chretien S. 2009. Direct binding of pRb/E2F-2 to GATA-1 regulates maturation and terminal cell division during erythropoiesis. PLoS Biol 7: e1000123. doi: 10.1371/journal.pbio.1000123.
20. Kim I, Saunders TL, Morrison SJ. 2007. Sox17 dependence distinguishes the transcriptional regulation of fetal from adult hematopoietic stem cells. Cell 130: 470-483. (Pubitemid 47208520)
21. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D. 2008. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111: 2991-2998.
22. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D. 2010. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 24: 478-490.
23. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, et al. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818-822. (Pubitemid 44258912)
24. Lackey J, Barnett J, Davidson L, Batty IH, Leslie NR, Downes CP. 2007. Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene 26: 7132-7142. (Pubitemid 350059678)
25. Lakshmikuttyamma A, Pastural E, Takahashi N, Sawada K, Sheridan DP, DeCoteau JF, Geyer CR. 2008. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 27: 3831-3844. (Pubitemid 351862064)
26. Li C, Wong WH. 2001. Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection. Proc Natl Acad Sci 98: 31-36. (Pubitemid 32095858)
27. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. 2005. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37: 613-619. (Pubitemid 40770416)
28. Mateyak MK, Obaya AJ, Sedivy JM. 1999. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19: 4672-4683.
29. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. 2004. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci 101: 3130-3135. (Pubitemid 38327746)
30. Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. 1995. The purification and characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci 92: 10302-10306.
31. Orkin SH. 1992. GATA-binding transcription factors in hematopoietic cells. Blood 80: 575-581.
32. Ouyang L, Jacob KK, Stanley FM. 1996. GABP mediates insulin-increased prolactin gene transcription. J Biol Chem 271: 10425-10428. (Pubitemid 26145772)
33. Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C. 2007. Incidence and clinical implications of GATA1mutations in newborns with Down syndrome. Blood 110: 2128-2131. (Pubitemid 47443931)
34. Pollak M. 2008. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
35. Porse BT, Pedersen TA, Xu X, Lindberg B, Wewer UM, Friis- Hansen L, Nerlov C. 2001. E2F repression by C/EBPa is required for adipogenesis and granulopoiesis in vivo. Cell 107: 247-258. (Pubitemid 33035950)
36. Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, DeRiel K, Gewirtz AM. 1994. A reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis. J Clin Invest 94: 320-327. (Pubitemid 24218107)
37. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos SC, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. 2005. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105: 2527-2534. (Pubitemid 40387055)
38. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. 2002. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev 16: 245-256.
39. Rowland BD, Bernards R. 2006. Re-evaluating cell-cycle regulation by E2Fs. Cell 127: 871-874.
40. Rylski M, Welch JJ, Chen YY, Letting DL, Diehl JA, Chodosh LA, Blobel GA, Weiss MJ. 2003. GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol 23: 5031-5042. (Pubitemid 36793347)
41. Sears R, Ohtani K, Nevins JR. 1997. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol 17: 5227-5235. (Pubitemid 27357621)
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550. (Pubitemid 41528093)
43. Thalmeier K, Synovzik H, Mertz R, Winnacker EL, Lipp M. 1989. Nuclear factor E2F mediates basic transcription and trans-activation by E1a of the human MYC promoter. Genes Dev 3: 527-536.
44. Tunstall-Pedoe O, Roy A, Karadimitris A, de la Fuente J, Fisk NM, Bennett P, Norton A, Vyas P, Roberts I. 2008. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 112: 4507-4511.
45. Voz ML, Mathys J, Hensen K, Pendeville H, Van Valckenborgh I, Van Huffel C, Chavez M, Van Damme B, De Moor B, Moreau Y, et al. 2004. Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene 23: 179-191. (Pubitemid 38142252)
46. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH. 2006. A protein interaction network for pluripotency of embryonic stem cells. Nature 444: 364-368. (Pubitemid 44764111)
47. Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD. 2002. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32: 148-152. (Pubitemid 34977210)
48. West MJ, Stoneley M, Willis AE. 1998. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 17: 769-780. (Pubitemid 28412498)
49. Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, et al. 2003. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102: 2960-2968. (Pubitemid 37248871)
50. Yang ZF, Mott S, Rosmarin AG. 2007. The Ets transcription factor GABP is required for cell-cycle progression. Nat Cell Biol 9: 339-346. (Pubitemid 46344614)
51. Zhang CC, Lodish HF. 2004. Insulin-like growth factor 2 expressed in a novel fetal liver cell population is a growth factor for hematopoietic stem cells. Blood 103: 2513-2521.